To evaluate the pharmacokinetic interactions of AD-231A, AD-231B, and AD-231C in healthy adult volunteers.
Study Type
INTERVENTIONAL
Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Enrollment
55
AD-231A Oral Tablet
AD-231B+AD-231C Oral Tablet
AD-231A+AD-231B+AD-231C Oral Tablet
H+ Yangji Hospital
Seoul, South Korea
Area under the plasma concentration-time curve during dosing interval at steady state (AUCτ,ss)
AUCτ,ss
Time frame: pre-dose (0hour) to 24 hours post-dose on Day 14
Maximum concentration of drug in plasma at steady state (Cmax,ss)
Time frame: pre-dose (0hour) to 24 hours post-dose on Day 14
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.